发明授权
- 专利标题： Spiroxazolidinone compounds
- 专利标题（中）： 螺恶唑烷酮化合物
-
申请号： US13810946申请日： 2011-08-12
-
公开(公告)号： US08742110B2公开(公告)日： 2014-06-03
- 发明人: Joseph L. Duffy , Jianming Bao , Debra L. Ondeyka , Sriram Tyagarajan , Patrick Shao , Feng Ye , Revathi Katipally , Aaron Zwicker , Edward C. Sherer , Michael A. Plotkin , Remond Moningka , Zahid Hussain , Harold B. Wood , Feroze Ujjainwalla , F. Anthony Romero , Paul E. Finke , Yi Zang , Weiguo Liu
- 申请人： Joseph L. Duffy , Jianming Bao , Debra L. Ondeyka , Sriram Tyagarajan , Patrick Shao , Feng Ye , Revathi Katipally , Aaron Zwicker , Edward C. Sherer , Michael A. Plotkin , Remond Moningka , Zahid Hussain , Harold B. Wood , Feroze Ujjainwalla , F. Anthony Romero , Paul E. Finke , Yi Zang , Weiguo Liu
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Janet E. Fair; Catherine D. Fitch
- 国际申请： PCT/US2011/047590 WO 20110812
- 国际公布： WO2012/024183 WO 20120223
- 主分类号： C07D215/00
- IPC分类号： C07D215/00 ; C07D229/00 ; A61K31/44 ; A61K31/397
摘要：
Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.
公开/授权文献
- US20130131042A1 SPIROXAZOLIDINONE COMPOUNDS 公开/授权日：2013-05-23
信息查询
